Assessment of malignancy and PSMA expression of uncertain bone foci in [
Biopsy
PET-guided
PET/CT
PSMA
Prostate cancer
Prostate-specific membrane antigen
[18F]-PSMA-1007
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
20
01
2022
accepted:
19
02
2022
pubmed:
29
4
2022
medline:
26
8
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [ A retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [ One out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate. This cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [
Identifiants
pubmed: 35482114
doi: 10.1007/s00259-022-05745-5
pii: 10.1007/s00259-022-05745-5
pmc: PMC9399054
doi:
Substances chimiques
Gallium Radioisotopes
0
Oligopeptides
0
PSMA-1007
0
Radiopharmaceuticals
0
Niacinamide
25X51I8RD4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3910-3916Informations de copyright
© 2022. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):642-651
pubmed: 31865408
Eur Radiol. 2021 Oct;31(10):8030-8039
pubmed: 33856522
Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2027-36
pubmed: 20680270
J Nucl Med. 2021 Feb;62(2):208-213
pubmed: 32817141
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483-4494
pubmed: 34120201
Eur Radiol. 2009 Jul;19(7):1780-5
pubmed: 19238391
EJNMMI Res. 2021 Jan 6;11(1):3
pubmed: 33409930
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
J Nucl Med. 2019 Sep;60(9):1270-1276
pubmed: 30737300
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2395-2404
pubmed: 33797596
Prostate Cancer Prostatic Dis. 2020 Jun;23(2):343-348
pubmed: 31780781
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):614-623
pubmed: 31792572
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1607-1608
pubmed: 28488027
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4495-4507
pubmed: 34136957
Nuklearmedizin. 2020 Feb;59(1):33-34
pubmed: 31766065
Theranostics. 2020 Jan 1;10(1):1-16
pubmed: 31903102
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
BJU Int. 2020 Sep;126(3):396-401
pubmed: 32592330
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2055-2061
pubmed: 30027419
Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):470-480
pubmed: 34402925
Eur J Nucl Med Mol Imaging. 2021 Nov 13;:
pubmed: 34773473
Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):486-95
pubmed: 23179945
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2978-2989
pubmed: 33550425